10-Q: BioVie Inc. Q3 2026: Increased Net Loss Amidst Clinical Trial Spending

BioVie Inc. reported a net loss of $5.3 million for the third quarter of fiscal year 2026, an increase from $2.8 million in the prior year, driven by higher research and development expenses for ongoing clinical trials.

Summary

• BioVie Inc. reported a net loss of $5.3 million for the three months ended March 31, 2026, compared to a net loss of $2.8 million for the same period in 2025.
• Total operating expenses increased to $5.4 million from $3.0 million, primarily due to a $1.9 million rise in research and development (R&D) expenses.
• R&D expenses were driven by increased activity in the Sunrise PD Phase 2 study and the Long COVID Phase 2 study.
• General and administrative expenses also saw an increase of $565,000, largely attributed to higher executive and director compensation, including stock-based compensation.
• The company had $13.1 million in cash and cash equivalents as of March 31, 2026, with a working capital of approximately $15.2 million.
• BioVie Inc. continues to operate in a pre-revenue stage, with its future viability dependent on securing additional financing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the increased net loss, rising operating expenses, and the continued substantial doubt regarding the company's ability to continue as a going concern, despite progress in clinical trials.

Positives

• The company has $13.1 million in cash and cash equivalents as of March 31, 2026, providing some operational runway.
• The Phase 2b Parkinson's Disease (PD) trial commenced in April 2025 and completed enrollment of 60 patients in December 2025, with topline results expected mid-year 2026.
• The Long COVID Phase 2 ADDRESS-LC study is progressing, with the FDA having authorized the IND application.
• The company received a $13.1 million clinical trial grant from the U.S. Department of Defense for the Long COVID program.
• The Phase 3 study for BIV201 for liver cirrhosis and ascites is in the protocol design finalization stage.

Negatives

• Net loss for the three months ended March 31, 2026, increased to $5.3 million from $2.8 million in the prior year.
• Total operating expenses increased significantly to $5.4 million from $3.0 million.
• Research and development expenses increased by $1.9 million, primarily due to increased clinical trial activities.
• General and administrative expenses increased by $565,000, driven by higher compensation costs.
• The company has an accumulated deficit of approximately $368.6 million.
• The company is in a pre-revenue stage and expects no revenues in the foreseeable future.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to its reliance on future financing.

Risks

• The company's future operations are dependent on the success of its development and commercialization efforts and its ability to secure additional financing.
• There is substantial doubt about the company's ability to continue as a going concern.
• Clinical trial results may not be favorable and may not support further development.
• The company may experience future dilution from equity offerings or the issuance of shares subject to options, warrants, and other arrangements.
• The company is subject to ongoing securities class action and shareholder derivative lawsuits, which could result in significant costs and potential damages.
• The company's drug candidates may not receive regulatory approval from the FDA or other regulatory bodies.
• Competition from other companies developing similar therapies could impact market share and profitability.

Future Outlook

The company's future operations are dependent on the success of its ongoing development and commercialization efforts, as well as its ability to secure additional financing. Management expects future funding sources may include sales of equity, loans, or other strategic transactions. There is no assurance that the company will be successful in obtaining sufficient financing to fund continuing operations, raising substantial doubt about its ability to continue as a going concern.

Management Comments

• The Company believes Bezisterim inhibits activation of inflammatory action extracellular single regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFB) that lead to neuroinflammation and insulin resistance.
• The Company believes that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID.
• The Company is currently finalizing the protocol design for the Phase 3 study of BIV201 with a focus on demonstrating clinical benefit through a composite primary endpoint of complications and disease progression in patients with cirrhosis and ascites who have recently recovered from acute kidney injury (AKI).
• The Company believes that the claims in the shareholder derivative lawsuits are without merit and intends to defend vigorously against them.

Industry Context

StockSavvy.ai notes that BioVie Inc.'s focus on neurological and neurodegenerative disorders, particularly Alzheimer's and Parkinson's disease, places it in a highly competitive and capital-intensive sector. The increasing understanding of the role of inflammation in these diseases aligns with BioVie's investigational drug bezisterim. However, the company faces significant challenges common to clinical-stage biotechs, including lengthy development timelines, high R&D costs, regulatory hurdles, and the critical need for continuous funding.

Comparison to Industry Standards

• Companies in the clinical-stage biopharmaceutical sector often exhibit significant net losses due to high R&D expenditures, similar to BioVie Inc.'s current financial state.
• The reliance on external financing, such as equity offerings, is a common strategy for companies like BioVie Inc. to fund ongoing clinical trials and operations, as seen in their August 2025 offering.
• The development of novel therapies for complex diseases like Alzheimer's and Parkinson's requires substantial investment, with many companies in this space not achieving profitability for many years, if at all.
• The pursuit of FDA Fast Track status and Orphan Drug designation, as achieved by BIV201, is a strategic approach used by many biotechs to expedite the development and review of drugs for serious conditions with unmet medical needs.

Legal Proceedings

• A consolidated securities class action lawsuit (In re BioVie Inc. Securities Litigation) is ongoing, alleging material misrepresentations and/or omissions related to the company's business and trials. Fact discovery is underway, and motions for class certification and leave to file a second amended complaint are pending.
• Three consolidated shareholder derivative lawsuits (In re BioVie Inc. Derivative Litigation) are stayed pending resolution of a summary judgment motion in the securities class action. These lawsuits allege breaches of fiduciary duties by current and former officers and directors.

Related Party Transactions

• The company acquired biopharmaceutical assets from NeurMedix, Inc., a privately held clinical-stage pharmaceutical company and a related party, in June 2021.
• The company is obligated to pay a low single-digit royalty on net sales of BIV201 to LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. pursuant to a merger agreement.

Stakeholder Impact

• Shareholders may experience future dilution due to potential equity offerings or the issuance of shares from options and warrants.
• The ongoing litigation could result in significant financial costs and potential damages, impacting shareholder value.
• Employees and management may be subject to increased scrutiny and potential liability due to ongoing legal proceedings.
• Creditors and suppliers may face increased risk if the company is unable to secure sufficient financing to continue operations.

Next Steps

• Report topline results from the Phase 2b Parkinson's Disease trial in mid-year 2026.
• Finalize the protocol design for the Phase 3 study of BIV201 for liver cirrhosis and ascites.
• Continue to pursue additional financing to fund operations.
• Engage in fact discovery for the securities class action litigation.
• Respond to the motion for class certification in the securities class action.

Key Dates

Recommendation

BioVie Inc. presents a high-risk, high-reward profile. While the company is making progress in its clinical trials for Parkinson's Disease, Long COVID, and liver cirrhosis, the significant increase in net loss, substantial accumulated deficit, and the ongoing 'going concern' doubt warrant caution. The pending litigation also adds considerable uncertainty. The potential for positive clinical trial results is a strong catalyst, but the immediate financial precariousness and legal challenges suggest a 'hold' recommendation until further clarity on financing and litigation outcomes emerges.

Keywords

BioVie Inc., Form 10-Q, Quarterly Report, Clinical Stage, Neurological Disorders, Neurodegenerative Disorders, Liver Disease, Bezisterim, NE3107, Parkinsons Disease, Alzheimers Disease, Long COVID, BIV201, Ascites, Clinical Trials, R&D Expenses, Net Loss, Going Concern